Susquehanna International Group
ALLO icon

Susquehanna International Group’s Allogene Therapeutics ALLO Stock Holding History

Susquehanna International Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$454K Buy
185,900
+89,700
+93% +$180K ﹤0.01% 9930
2025
Q4 		$132K Buy
96,200
+48,200
+100% +$63.6K ﹤0.01% 11270
2025
Q3 		$59.5K Sell
48,000
-26,100
-35% -$31.1K ﹤0.01% 11803
2025
Q2 		$83.7K Sell
74,100
-53,900
-42% -$71.6K ﹤0.01% 11884
2025
Q1 		$187K Buy
128,000
+108,900
+570% +$205K ﹤0.01% 11006
2024
Q4 		$40.7K Sell
19,100
-21,900
-53% -$54K ﹤0.01% 11751
2024
Q3 		$115K Sell
41,000
-39,600
-49% -$106K ﹤0.01% 10954
2024
Q2 		$188K Sell
80,600
-14,200
-15% -$41.9K ﹤0.01% 10457
2024
Q1 		$424K Buy
+94,800
New +$396K ﹤0.01% 8911
2023
Q2 		– Sell
-12,700
Closed -$62.7K – 11976
2023
Q1 		$62.7K Sell
12,700
-8,900
-41% -$57.1K ﹤0.01% 11590
2022
Q4 		$136K Sell
21,600
-1,000
-4% -$9.26K ﹤0.01% 10638
2022
Q3 		$244K Sell
22,600
-15,100
-40% -$205K ﹤0.01% 10323
2022
Q2 		$430K Sell
37,700
-26,900
-42% -$239K ﹤0.01% 8636
2022
Q1 		$589K Buy
64,600
+29,700
+85% +$309K ﹤0.01% 8553
2021
Q4 		$521K Sell
34,900
-300
-0.9% -$5.29K ﹤0.01% 9085
2021
Q3 		$905K Buy
+35,200
New +$836K ﹤0.01% 7836
2021
Q2 		– Sell
-18,500
Closed -$653K – 12496
2021
Q1 		$653K Buy
+18,500
New +$624K ﹤0.01% 8842
2020
Q4 		– Sell
-76,600
Closed -$2.89M – 10961
2020
Q3 		$2.89M Sell
76,600
-42,500
-36% -$1.6M ﹤0.01% 3928
2020
Q2 		$5.1M Buy
119,100
+78,400
+193% +$2.84M ﹤0.01% 2982
2020
Q1 		$791K Sell
40,700
-5,800
-12% -$138K ﹤0.01% 5914
2019
Q4 		$1.21M Sell
46,500
-165,700
-78% -$4.56M ﹤0.01% 5159
2019
Q3 		$5.78M Buy
212,200
+152,000
+252% +$4.33M ﹤0.01% 2531
2019
Q2 		$1.62M Buy
60,200
+9,300
+18% +$259K ﹤0.01% 4599
2019
Q1 		$1.47M Buy
50,900
+35,300
+226% +$1.02M ﹤0.01% 4270
2018
Q4 		$420K Buy
+15,600
New +$414K ﹤0.01% 6360

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's ALLO Position: Q1 2026 in Review

Susquehanna International Group increased its Allogene Therapeutics (ALLO) stake by 39% in Q1 2026, buying an estimated $71.2K and bringing the position to 126,760 shares worth $309K. The position accounts for ﹤0.01% of the portfolio, ranked #10791.

Susquehanna International Group first reported a position in ALLO in Q2 2019 and has held it in 27 quarters since. The position peaked at $5.45M in Q1 2021. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Susquehanna International Group held 126,760 shares of Allogene Therapeutics worth $309K as of Q1 2026.
  • Susquehanna International Group bought 35,507 Allogene Therapeutics shares in Q1 2026, an estimated $71.2K.
  • Allogene Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10791 holding.
  • Susquehanna International Group first reported a position in Allogene Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Susquehanna International Group's Allogene Therapeutics position peaked at $5.45M in Q1 2021.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.